| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 6e-08 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.33 | 8e-08 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 6e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.29 | 1e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.24 | 1e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.22 | 4e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.14 | 9e-05 |